In October 2022, NHS England published the Accelerating Genomic Medicine in the NHS Strategy, which included a plan to establish ‘NHS Genomic Networks of Excellence’ as part of its commitment to provide a world-leading NHS Genomic Medicine Service (GMS) which provides cutting-edge benefits for patients in the NHS.
Eight innovative networks have recently been launched, to develop the evidence and model of adoption for cutting edge genomic advances and technology applications that will be transformative for patients. Each network forms part of the existing Genomic Medicine Service Alliance (GMSA).
The networks are designed to work collabortively within the NHS, as well as with academia, third sector organisations and industry, to utilise expertise and resources across the wider genomics landscape.
Following a rigorous process, reviewed by NHS England's Genomics Unit, NHS England national clinical directors, national specialty advisors, the Office for Life Sciences, Genomics England and other key stakeholders, the following networks of excellence have been established:
- Prenatal genomic medicine
- Circulating tumour biomarker testing
- Rare and inherited disease
- Severe presentation of infectious disease
- Improving the identification and outcomes for individuals with inherited and acquired cardiovascular disease
- Pharmacogenomic and medicines optimisation
- Genomics artificial intelligence (AI)
Dame Sue Hill, Chief Scientific Officer for England has recently produced a blog article, available to read on NHS England's website.
More information will follow over the coming weeks and months, so please bookmark our news page for future updates.